ELSEVIER

Atherosclerosis 119 (1996) 265–267

atherosclerosis

Author index

Volume 119 (1996)

Andersson, A., see Wiklund, O. **119**, 99
Arveiler, D., see Lane, A. **119**, 119

Bara, L., see Lane, A. **119**, 119
Bauer, J., see Lucas, A. **119**, 17
Bétard, C., A.M. Kessling, M. Roy, J. Davignon, Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a 'null' LDL-receptor gene defect **119**, 43
Bondjers, G., see Wiklund, O. **119**, 57
Boomsma, D.I., see Hoffer, M.J.V. **119**, 159
Borch-Johnsen, K., see Skov Jensen, J. **119**, 69
Bravo, E., G. Ortu, R. Rivabene, M.T. Santini, A. Cantafora, Probucol reduces hepatic cholesterol secretion in hyperlipidemic Yoshida rats **119**, 223
Bräutigam, C., B. Engelmann, D. Reiss, U. Reinhardt, J. Thiery, W.O. Richter, T. Brosche, Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis **119**, 77
Bredie, S.J.H., see Hoffer, M.J.V. **119**, 159
Brennan, C., see Jones, R.J. **119**, 151
Brosche, T., see Bräutigam, C. **119**, 77

Cambien, F., see Lane, A. **119**, 119
Cambou, J.P., see Lane, A. **119**, 119
Camejo, G., see Wiklund, O. **119**, 57
Cantafora, A., see Bravo, E. **119**, 223
Cantin, B., see Lamarche, B. **119**, 235
Chagpar, A., see Lucas, A. **119**, 17
Chung, T.K.H., see Haines, C.J. **119**, 215
Collins, P.B., see Jones, R.J. **119**, 151

Dagenais, G.R., see Lamarche, B. **119**, 235
Dai, E., see Lucas, A. **119**, 17
Darley-Usmar, V., see O'Leary, V.J. **119**, 169
Davignon, J., see Bétard, C. **119**, 43
de Knijff, P., see Hoffer, M.J.V. **119**, 159
Demacker, P.N.M., see Hoffer, M.J.V. **119**, 159
Després, J.-P., see Lamarche, B. **119**, 235
Dobmeyer, J., J. Lohrmann, G. Feussner, Prevalence and association of atherosclerosis at three different arterial sites in patients with type III hyperlipoproteinemia **119**, 89

Engelmann, B., see Bräutigam, C. **119**, 77
Evans, A., see Lane, A. **119**, 119

Fager, G., see Wiklund, O. **119**, 99
Feldt-Rasmussen, B., see Skov Jensen, J. **119**, 69
Feussner, G., see Dobmeyer, J. **119**, 89
Firth, J.C., see Naoumova, R.P. **119**, 203
Fleetwood, G., see O'Leary, V.J. **119**, 169
Frants, R.R., see Hoffer, M.J.V. **119**, 159
Fuller, C.J., S.M. Grundy, E.P. Norkus, I. Jialal, Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers **119**, 139

Garbutt, M., see Lucas, A. **119**, 17
Gnasso, A., C. Irace, P.L. Mattioli, A. Pujia, Carotid intima–media thickness and coronary heart disease risk factors **119**, 7
Green, F., see Lane, A. **119**, 119
Grundy, S.M., see Fuller, C.J. **119**, 139

Hakamata, H., see Sakai, M. **119**, 191
Havekes, L.M., see Hoffer, M.J.V. **119**, 159
He, Y., W.C.P. Kwan, U.P. Steinbrecher, Effects of oxidized low density lipoprotein on endothelin secretion by cultured endothelial cells and macrophages **119**, 107
Horiuchi, S., see Sakai, M. **119**, 191
Hoffer, M.J.V., S.J.H. Bredie, D.I. Boomsma, P.W.A. Reymer, J.J.P. Kastelein, P. de Knijff, P.N.M. Demacker, A.F.H. Stalenhoef, L.M. Havekes, R.R. Frants, The lipoprotein lipase (Asn291 → Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia **119**, 159
Hultberg, B., see Wiklund, O. **119**, 99
Humphries, S., see Lane, A. **119**, 119

Irace, C., see Gnasso, A. **119**, 7

Jensen, G., see Skov Jensen, J. **119**, 69
Haines, C.J., T.K.H. Chung, J.R.L. Masarei, B. Tomlinson, J.T.F. Lau, An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins **119**, 215
Jialal, I., see Fuller, C.J. **119**, 139
Jiang, X.Y., see Lucas, A. **119**, 17
Johnson, A.H., see Jones, R.J. **119**, 151
Jokela, H., see Nikkilä, M. **119**, 181
Jones, R.J., D. Owens, C. Brennan, P.B. Collins, A.H. Johnson, G.H. Tomkin, Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in Type 2 diabetes: relationship to serum lipoproteins A-I and A-II **119**, 151

Kang, S.-S., P.W.K. Wong, Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia **119**, 135
Kappagoda, C.T., see Skepper, J.N. **119**, 247
Kastelein, J.J.P., see Hoffer, M.J.V. **119**, 159
Kessling, A.M., see Bétard, C. **119**, 43
Kobori, S., see Sakai, M. **119**, 191
Koivula, T., see Nikkilä, M. **119**, 181
Kwan, W.C.P., see He, Y. **119**, 107

Laippala, P., see Nikkilä, M. **119**, 181
Lamarche, B., J.-P. Després, S. Moorjani, B. Cantin, G.R. Dagenais, P.-J. Lupien, Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study **119**, 235
Lane, A., F. Green, P.Y. Scarabin, V. Nicaud, L. Bara, S. Humphries, A. Evans, G. Luc, J.P. Cambou, D. Arveiler, F. Cambien, Factor VII Arg/Gin_{353} polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTM study **119**, 119
Lau, J.T.F., see Haines, C.J. **119**, 215
Lehtimäki, T., see Nikkilä, M. **119**, 181
Lehtomäki, E., see Nikkilä, M. **119**, 181
Liu, L.-y., see Lucas, A. **119**, 17
Lohrmann, J., see Dobmeyer, J. **119**, 89
Luc, G., see Lane, A. **119**, 119
Lucas, A., W. Yue, X.Y. Jiang, L.-y. Liu, W.-d. Yan, J. Bauer, W. Schneider, J. Tulip, A. Chagpar,
Lundstam, U., see Wiklund, O. **119**, 99
Lupien, P.-J., see Lamarche, B. **119**, 235

Marais, A.D., see Naoumova, R.P. **119**, 203
Masarei, J.R.L., see Haines, C.J. **119**, 215
Masson, P., see Wiklund, O. **119**, 99
Mattioli, P.L., see Gnasso, A. **119**, 7
Miyazaki, A., see Sakai, M. **119**, 191
Montague, P., see Lucas, A. **119**, 17
Moorjani, S., see Lamarche, B. **119**, 235
Morikawa, W., see Sakai, M. **119**, 191
Mountney, J., see Naoumova, R.P. **119**, 203

Naoumova, R.P., A.D. Marais, J. Mountney, J.C. Firth, N.B. Rendell, G.W. Taylor, G.R. Thompson, Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia **119**, 203
Nicaud, V., see Lane, A. **119**, 119
Nikkilä, M., T. Pitkäjärvi, T. Koivula, T. Solakivi, T. Lehtimäki, P. Laippala, H. Jokela, E. Lehtomäki, K. Seppä,
Norkus, E.P., see Fuller, C.J. **119**, 139
Nourooz-Zadeh, J., see Wolff, S.P. **119**, 261

O'Leary, V.J., L. Tilling, G. Fleetwood, D. Stone, V. Darley-Usmar, The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy **119**, 169
Ortu, G., see Bravo, E. **119**, 223
Owens, D., see Jones, R.J. **119**, 151

Perk, M., see Lucas, A. **119**, 17
Pitkäjärvi, T., see Nikkilä, M. **119**, 181
Puddey, I.B.,Review article Low serum cholesterol and the risk of cerebral haemorrhage **119**, 1
Pujia, A., see Gnasso, A. **119**, 7

Radosavljevic, M., see Lucas, A. **119**, 17
Reinhardt, U., see Bräutigam, C. **119**, 77
Reiss, D., see Bräutigam, C. **119**, 77
Rendell, N.B., see Naoumova, R.P. **119**, 203
Reymer, P.W.A., see Hoffer, M.J.V. **119**, 159
Richter, W.O., see Bräutigam, C. **119**, 77
Rivabene, R., see Bravo, E. **119**, 223
Roy, M., see Bétard, C. **119**, 43

Sakai, M., A. Miyazaki, H. Hakamata, Y. Suginohara, Y.-I. Sakamoto, W. Morikawa, S. Kobori, M. Shichiri, S. Horiuchi, Reconstituted high density lipoprotein reduces the capacity of oxidatively modified low density lipoprotein to accumulate cholesteryl esters in mouse peritoneal macrophages **119**, 191
Sakamoto, Y.-I., see Sakai, M. **119**, 191
Santini, M.T., see Bravo, E. **119**, 223
Scarabin, P.Y., see Lane, A. **119**, 119
Schneider, W., see Lucas, A. **119**, 17
Seppä, K., see Nikkilä, M. **119**, 181
Shichiri, M., see Sakai, M. **119**, 191
Sillanaukee, P., see Nikkilä, M. **119**, 181
Skepper, J.N., C.T. Kappagoda, The effect of isradipine administration on existing fatty streaks in the cholesterol-fed rabbit: A morphometric study **119**, 247
Skov Jensen, J., K. Borch-Johnsen, G. Jensen, B. Feldt-Rasmussen, Insulin sensivity in clinically healthy individuals with microalbuminuria **119**, 69
Solakivi, T., see Nikkilä, M. **119**, 181
Stalenhoef, A.F.H., see Hoffer, M.J.V. **119**, 159
Steinbrecher, U.P., see He, Y. **119**, 107
Stone, D., see O'Leary, V.J. **119**, 169
Suginohara, Y., see Sakai, M. **119**, 191

Taylor, G.W., see Naoumova, R.P. **119**, 203

Thiery, J., see Bräutigam, C. **119**, 77
Thompson, G.R., see Naoumova, R.P. **119**, 203
Tilling, L., see O'Leary, V.J. **119**, 169
Tomkin, G.H., see Jones, R.J. **119**, 151
Tomlinson, B., see Haines, C.J. **119**, 215
Tulip, J., see Lucas, A. **119**, 17

Wiklund, O., G. Bondjers, I. Wright, G. Camejo, Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs **119**, 57
Wiklund, O., G. Fager, A. Andersson, U. Lundstam, P. Masson, B. Hultberg, *N*-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels **119**, 99
Wolff, S.P., J. Nourooz-Zadeh, Hypothesis: UK consumption of dietary lipid hydroperoxides — a possible contributory factor to atherosclerosis **119**, 261
Wong, P.W.K., see Kang, S.-S. **119**, 135
Wright, I., see Wiklund, O. **119**, 57

Yan, W.-d., see Lucas, A. **119**, 17
Yue, W., see Lucas, A. **119**, 17

ELSEVIER

Atherosclerosis 119 (1996) 269–270

atherosclerosis

Subject index

Volume 119 (1996)

Alcohol **119**, 235
Alpha tocopherol **119**, 77
Apolipoprotein A-II **119**, 151
Apolipoprotein E **119**, 89, 181
Apoprotein A-1 **119**, 151
Ascorbate **119**, 139
Atherosclerosis **119**, 7, 17, 57, 89, 107, 169
Atherosclerotic vascular disease **119**, 69
Atorvastatin **119**, 203
Avian model **119**, 17

Bile **119**, 223
Blood pressure **119**, 69
Body weight **119**, 69

Cerebral haemorrhage **119**, 1
Cholesterol **119**, 223, 235, 247
Cholesterol **119**, 159
Cholesterol biosynthesis **119**, 203
Cholesteryl ester transfer protein **119**, 151
Coronary artery disease **119**, 181
Coronary heart disease **119**, 215
Cysteine **119**, 99

Dietary lipid **119**, 261
Digitonin **119**, 247
Discoidal HDL **119**, 191
Dysbetalipoproteinemia **119**, 89

Echo-Doppler **119**, 7
ECTIM **119**, 119
Endothelial cells **119**, 107
Endothelin **119**, 107

Factor VII Arg/Gln_{353} polymorphism **119**, 119
Factor VII coagulant activity **119**, 119
Familial combined hyperlipidaemia **119**, 159
Familial hypercholesterolaemia **119**, 203
Familial hypercholesterolemia **119**, 43
Fatty streak **119**, 247
Foam cell formation **119**, 191

Free radicals **119**, 139

Genetic defects **119**, 135

Haplotype **119**, 43
HDL **119**, 77
HDL-C **119**, 235
Homocysteine **119**, 99
Homocystinuria **119**, 135
Hydroperoxides **119**, 261
Hyperhomocyst(e)inemia **119**, 135
Hyperlipidemia **119**, 57, 223

Inheritance **119**, 135
Insulin sensivity **119**, 69
Isradipine **119**, 247

LDL **119**, 139
LDL oxidation **119**, 169
LDL receptor **119**, 43
LDL size **119**, 181
Lecithin:cholesterol acyltransferase **119**, 151
Lipid lowering therapy **119**, 1
Lipids **119**, 69
Lipoprotein **119**, 223
Lipoprotein(a) **119**, 99, 215
Lipoprotein lipase **119**, 159
Lipoproteins **119**, 57, 215
Liver **119**, 223
Low density lipoprotein **119**, 181
LPL(Asn291 → Ser) mutation **119**, 159

Macrophages **119**, 107
Macrophage scavenger receptor(s) **119**, 191
Menopause **119**, 215
Microalbuminuria **119**, 69
MI risk factors **119**, 119
Morphometry **119**, 247

N-acetylcysteine **119**, 99

Oxidation **119**, 139
Oxidized LDL **119**, 107, 191

Phospholipid transfer **119**, 191
Plasma mevalonic acid **119**, 203
Plasmenylcholine **119**, 77
Plasmenylethanolamine **119**, 77
Polyunsaturated fatty acids **119**, 77
Pravastatin **119**, 203
Probucol **119**, 169
Proteoglycans **119**, 57

Rats **119**, 223
Red blood cell membranes **119**, 77
Regression **119**, 247
Restenosis **119**, 17
Risk Factors **119**, 235

Serum cholesterol **119**, 1
Simvastatin **119**, 203
Smoking **119**, 139

Thrombosis risk factors **119**, 119
Triglycerides **119**, 159, 235
Type 2 diabetes **119**, 151
Type III hyperlipoproteinemia **119**, 89

Ultrasound **119**, 7

Vascular disease **119**, 135

Watanabe rabbits **119**, 169